Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

A Maryland drug affordability board can move forward with a plan to cap how much the state and local governments pay for ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...

Roche CEO Urges FTC to Block Novo Nordisks Acquisition of Catalent Roches CEO, Thomas Schinecker, has called on authorities ...

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to ...

Global Thrombocytopenia Treatment IndustryThe global Thrombocytopenia Treatment Market is projected to experience significant ...

Roivant's high valuation is justified, with a strong cash position, promising drug pipeline, and strategic partnerships ...